RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Natarajan, G., Sriidhar, A., Nolen, T., Gantz, M., Das, A., Bell, E., Hintz, S., Bliss, J., Greenberg, R., & Shankaran, S. (2020). Authors' response. Pediatrics, 145(4), Article e20200056B. https://doi.org/10.1542/peds.2020-0056b
We thank Dr Rodriguez for her insightful comments on our article in which we report neurodevelopmental outcomes of preterm infants with retinopathy treated with bevacizumab or laser surgery. We agree entirely that the results of our nonrandomized study are confounded by baseline differences between groups and the likelihood that treatment options varied by center and over time, a point that is emphasized throughout the article.
For statistical adjustment, before embarking on the analysis, we a priori chose covariates known to be associated with neurodevelopmental outcomes in preterm infants, such as gestational age, sex, severe intracranial hemorrhage (ICH) or WMI, bronchopulmonary dysplasia (BPD), surgical necrotizing enterocolitis, and maternal public insurance, while controlling for center as a random effect. We did not include birth weight because of its collinearity with gestational age. We did not include duration of ventilator support or supplemental oxygen because of collinearity …
